Understanding Type 2 Diabetes

Overview of the Condition

Type 2 diabetes is a metabolic disorder that impairs an individual’s ability to process glucose, resulting in elevated blood glucose levels. This condition arises from either insufficient production of insulin, the hormone responsible for glucose regulation, or from insulin resistance, where the body cannot effectively use existing insulin.

Prevalence of Type 2 Diabetes

Globally, type 2 diabetes affects millions, with approximately 90% of diabetes patients in Canada diagnosed with this form of the disease.

Impact on Kidney Function and Ion Balance

Managing diabetes often involves medications such as canagliflozin, which enhances the kidneys’ ability to eliminate glucose, thereby normalizing blood sugar levels. However, the kidneys play a vital role in maintaining the body’s overall ion balance. A significant alteration in blood glucose can disrupt the levels of other ions regulated by the kidneys, potentially leading to imbalances in calcium, phosphate, and vitamin D. Such imbalances may increase the absorption of these ions from bone, compromising bone strength and heightening fracture risk in type 2 diabetes patients using canagliflozin.

Comparison of Diabetes Medications

GLP-1 Agonists and Fracture Risk

Another class of diabetes medications is glucagon-like peptide-1 (GLP-1) agonists, which are believed to carry a lower risk of causing fractures compared to other treatments. Despite this assumption, there is limited comparative data available regarding these medications.

Study on Fracture Risks

To address this gap, researchers from Brigham and Women’s Hospital in the United States conducted a study comparing fracture risks between patients using canagliflozin and those on GLP-1 agonists. The study analyzed data from 79,974 patients in each group, using information from U.S.-based commercial medical databases covering over 70 million individuals. The participants had a mean age of 55 years.

Findings of the Research

The study evaluated fracture risks in various bones, including the pelvic, hip, humerus, radius, ulna, carpal, metacarpal, metatarsal, and ankle. Results indicated similar fracture incidence rates among both patient groups. The findings concluded that for middle-aged patients, the fracture risk associated with canagliflozin was comparable to that of patients taking GLP-1 agonists.

Implications for Patient Counseling

Given these findings, the researchers recommend reassessing the information provided to patients regarding the potential side effects of these diabetes medications.

Reference

Fralick, M., Kim, S. C., Schneeweiss, S., Kim, D., Redelmeier, D. A., & Patorno, E. (2019). Fracture risk after initiation of use of canagliflozin: A cohort study. Annals of Internal Medicine. doi:10.7326/M18-0567